Fighting for Psilocybin Access: Inside the Right-to-Try and Rescheduling Effort

For patients with life-threatening conditions, access to promising treatments isn’t just policy, it’s a matter of compassion and dignity. That’s why, along with my co-counsel Shane Pennington, I have been leading the effort to reschedule psilocybin at the federal level.

In this conversation hosted by Psychedelics Today as part of their Advocacy Spotlight Initiative, Shane and I dive deep into the legal battle for psilocybin access and the broader implications for psychedelic medicine reform.

Here’s what we cover in this discussion:

• The multi-year legal strategy behind the psilocybin rescheduling petition
• How the Right-to-Try Act provides a pathway for patients seeking access to psilocybin therapy
• A behind-the-scenes look at the DEA and HHS review process for scheduling decisions
• What a post-rescheduling future might mean for patients, researchers, and healthcare providers

The interest to reschedule psilocybin is not only about advancing science and policy it’s about ensuring that patients and families have the right to explore all possible avenues for deeply-personal, sensitive care.

Please watch the replay of this important conversation to better understand what’s at stake, what progress has been made, and how far we still have to go.

For more information on this work, see our page dedicated to the DEA Petition here.

This video runs for 1:04:04 in total.

Kathryn Tucker, is the the National Psychedelic Association’s Special Advocacy Advisor.

Photo by Priscilla Du Preez on Unsplash.